Passage Bio Stock Market Value
| PASG Stock | USD 10.99 1.08 8.95% |
| Symbol | Passage |
Can Stock industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Passage Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Passage Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Passage Bio.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in Passage Bio on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding Passage Bio or generate 0.0% return on investment in Passage Bio over 90 days. Passage Bio is related to or competes with NuCana PLC, MetaVia, Lisata Therapeutics, Allarity Therapeutics, CytoMed Therapeutics, Enlivex Therapeutics, and Cingulate. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases More
Passage Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Passage Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Passage Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.01 | |||
| Information Ratio | 0.1287 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.77) | |||
| Potential Upside | 14.59 |
Passage Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Passage Bio's standard deviation. In reality, there are many statistical measures that can use Passage Bio historical prices to predict the future Passage Bio's volatility.| Risk Adjusted Performance | 0.1082 | |||
| Jensen Alpha | 0.9115 | |||
| Total Risk Alpha | 0.6411 | |||
| Sortino Ratio | 0.1565 | |||
| Treynor Ratio | 0.214 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Passage Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Passage Bio February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1082 | |||
| Market Risk Adjusted Performance | 0.224 | |||
| Mean Deviation | 5.99 | |||
| Semi Deviation | 6.33 | |||
| Downside Deviation | 7.01 | |||
| Coefficient Of Variation | 741.16 | |||
| Standard Deviation | 8.53 | |||
| Variance | 72.74 | |||
| Information Ratio | 0.1287 | |||
| Jensen Alpha | 0.9115 | |||
| Total Risk Alpha | 0.6411 | |||
| Sortino Ratio | 0.1565 | |||
| Treynor Ratio | 0.214 | |||
| Maximum Drawdown | 58.13 | |||
| Value At Risk | (9.77) | |||
| Potential Upside | 14.59 | |||
| Downside Variance | 49.17 | |||
| Semi Variance | 40.06 | |||
| Expected Short fall | (6.57) | |||
| Skewness | 1.3 | |||
| Kurtosis | 5.18 |
Passage Bio Backtested Returns
Passage Bio is moderately volatile given 3 months investment horizon. Passage Bio maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. We are able to interpolate and collect twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.15% are justified by taking the suggested risk. Use Passage Bio Semi Deviation of 6.33, risk adjusted performance of 0.1082, and Coefficient Of Variation of 741.16 to evaluate company specific risk that cannot be diversified away. Passage Bio holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 5.33, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. Use Passage Bio expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Passage Bio.
Auto-correlation | -0.08 |
Very weak reverse predictability
Passage Bio has very weak reverse predictability. Overlapping area represents the amount of predictability between Passage Bio time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Passage Bio price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Passage Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 7.79 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Passage Bio Correlation, Passage Bio Volatility and Passage Bio Performance module to complement your research on Passage Bio. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Passage Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.